the-lancet-respiratory-medicine

The Lancet Respiratory Medicine (the-lancet-respiratory-medicine)

Journal positioning

The Lancet Respiratory Medicine is a Lancet specialty journal for high-impact clinical

and population research across respiratory medicine and critical care — asthma, COPD,

interstitial and pulmonary vascular disease, respiratory infection, sleep and

ventilation, lung cancer screening, and intensive-care/critical-care medicine. It

favors **practice-changing randomized trials, major prospective cohorts, and analyses

with clear international clinical or policy consequence**, with a strong emphasis on

methodological rigor, generalizable populations, and patient-important outcomes. Small

single-center series, mechanistic/basic-science work without a clinical endpoint, and

incremental subgroup re-analyses are a weak fit and belong in a translational or

broader-scope respiratory journal. This skill is a **fit / venue-selection /

re-framing** aid; it is not clinical or regulatory advice and does not replace the

journal's current instructions for authors. Before submitting, re-check the live The

Lancet Respiratory Medicine author instructions.

When to trigger

• The author names The Lancet Respiratory Medicine for a respiratory or critical-care

clinical/population study and wants a fit/framing check.

• A trial or large cohort must be re-framed around an international, practice-changing

respiratory or critical-care question.

• The author is choosing between The Lancet Respiratory Medicine, the ATS "Blue

Journal", and general medicine.

• The author needs the journal's reporting-guideline, registration, and desk-reject

expectations for respiratory/critical-care evidence.

Scope & topic fit

• Randomized trials in airways disease (asthma, COPD), pulmonary vascular and

interstitial lung disease, respiratory infection, and sleep/ventilation.

• Critical-care and intensive-care trials and cohorts (ARDS, mechanical ventilation,

sepsis-related respiratory failure) with patient-important outcomes.

• Large prospective cohorts and high-quality observational studies addressing

respiratory disease burden, prognosis, or treatment effect at scale.

• Lung-cancer screening, diagnosis, and prevention studies with population-level or

practice-changing implications.

• Pragmatic and implementation trials, and well-powered diagnostic studies, relevant to

respiratory or critical-care practice internationally.

• Systematic reviews and meta-analyses that resolve a focused, clinically consequential

respiratory question.

Method & evidence bar

• Trials must be adequately powered with prespecified, patient-important primary

outcomes (mortality, exacerbations, lung function with clinical anchoring, quality of

life); surrogate-only endpoints need strong justification.

• The applicable reporting guideline and completed checklist are expected: CONSORT for

trials, STROBE for observational studies, PRISMA for systematic reviews, STARD for

diagnostic accuracy.

• Trials require prospective registration; the registration number, protocol, and

statistical-analysis plan are expected, with an independent data-monitoring rationale

where relevant.

• Observational and critical-care cohort claims must address confounding, immortal-time

and selection bias, and missing data; causal language must match the design.

• Effect estimates need confidence intervals and absolute as well as relative measures;

generalizability across settings/populations should be argued, not assumed.

• Multi-center and international evidence strengthens fit; single-center critical-care

series rarely clear the bar without exceptional outcomes.

Structure & house style

• Lancet specialty format with a structured summary and a Research in context /

evidence-before-this-study panel; re-check current article types and limits on the

live guide.

• The introduction frames the international clinical or policy gap; the discussion

states the practice consequence and limitations plainly.

• A CONSORT/STROBE/PRISMA flow diagram is expected where applicable; tables/figures

follow Lancet statistical-reporting standards.

• The role of the funding source statement and a data-sharing statement are expected;

appendices carry protocol, full statistical methods, and additional analyses.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and

../../resources/official-source-map.md; start from the ICMJE/EQUATOR and Lancet

anchors, then cite the current The Lancet Respiratory Medicine page you checked.

• Search the live site for "The Lancet Respiratory Medicine information for authors" and

follow the current version.

• Re-check article types, structured-summary and Research in context format, and

word/reference/figure limits.

• Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/STARD),

protocol/SAP, the role-of-funding-source statement, and data-sharing statement.

• Re-check IRB/ethics and consent, ICMJE authorship and conflict-of-interest disclosure,

funding, and AI-use disclosure.

• If the live official instructions conflict with this skill, the official instructions

win.

Pre-submission self-check

• [ ] The study answers an international, practice-changing respiratory or critical-care question.
• [ ] The primary outcome is prespecified and patient-important; the study is adequately powered.
• [ ] The correct reporting checklist (CONSORT/STROBE/PRISMA/STARD) is completed and attached.
• [ ] Trials are prospectively registered with the number in the manuscript; protocol/SAP provided.
• [ ] Confounding, selection/immortal-time bias, and missing data are addressed; causal language matches the design.
• [ ] IRB/consent, ICMJE disclosures, role-of-funding-source, and a data-sharing statement are prepared.

Common desk-reject triggers

• Single-center or underpowered respiratory/critical-care studies with limited generalizability and no practice change.
• Mechanistic or basic-science work with no clinical endpoint, better suited to a translational journal.
• Surrogate-only endpoints (e.g., a lung-function change with no clinical anchoring) presented as definitive.
• Missing trial registration, protocol, or the required reporting checklist.
• Observational analyses with inadequate confounding control or overstated causal claims.
• Narrow or incremental scope without international clinical or policy consequence.

Re-routing decision

• Translational, mechanistic, or basic-plus-clinical respiratory science → american-journal-of-respiratory-and-critical-care-medicine (ATS "Blue Journal", broader scope).
• Diabetes/endocrine or metabolic respiratory comorbidity dominant → the-lancet-diabetes-and-endocrinology.
• Population/policy framing without a clinical respiratory endpoint → the-lancet-public-health.
• Lung-cancer therapeutics as the core oncology contribution → annals-of-oncology / jama-oncology.
• Broad, practice-changing significance beyond respiratory specialty → general medicine (jama / NEJM / The Lancet in the natural-science bundle).

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] The Lancet Respiratory Medicine
[Specialty tags] <2–3 closest respiratory/critical-care topics>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / diagnostic-STARD>
[Method/evidence] <power, design, registration, generalizability — does it clear the practice-changing bar?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / role-of-funding / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>